MaxCyte MXCT Business Segments — Core Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MaxCyte in its filing.
Tagged under the XBRL concept mxct:CoreRevenue.
The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about MaxCyte's business segments — core revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MaxCyte's business segments — core revenue?
- MaxCyte (MXCT) reported business segments — core revenue of $6.22M in Q1 2026.
- How has MaxCyte's business segments — core revenue changed year-over-year?
- MaxCyte's business segments — core revenue decreased by 24.6% year-over-year, from $8.24M to $6.22M.
- What is the long-term trend for MaxCyte's business segments — core revenue?
- Over 2 years (2023 to 2025), MaxCyte's business segments — core revenue has grown at a -0.4% compound annual growth rate (CAGR), from $29.82M to $29.6M.
- What does business segments — core revenue mean?
- Represents the primary revenue generated from the company's core business activities, specifically the sale and licensing of proprietary cell engineering platform technologies. This metric reflects the fundamental commercial traction of the company's main product offerings within the life sciences market.